Product image of Lanreotid Zentiva (Lanreotide) supplied by GNH India

Lanreotid Zentiva

Active Ingredient:
Lanreotide
Origin:
EU

Lanreotid Zentiva (Lanreotide)

Lanreotide, the active ingredient in Lanreotid Zentiva, is a somatostatin analog presented as a sterile solution for subcutaneous injection. It is used to control excess growth hormone secretion in acromegaly and to inhibit hormone‑producing neuroendocrine tumors in adult patients.

GNH India supplies Lanreotid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality‑assured product availability across regulated markets. The product complies with European Union marketing authorisation standards and is distributed under strict cold‑chain conditions.

Manufacturer / TM Owner

Zentiva Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lanreotid Zentiva (lanreotide) is employed in the management of disorders driven by excess growth hormone or peptide hormone secretion.
  • Acromegaly: reduces serum IGF‑1 levels and controls disease activity.
  • Neuroendocrine tumors (e.g., carcinoid): alleviates hormone‑related symptoms and may slow tumor progression.
  • VIPoma: suppresses vasoactive intestinal peptide secretion, improving diarrhoea and electrolyte balance.

How It Works

  • Lanreotide is a synthetic analogue of somatostatin that binds with high affinity to somatostatin receptor subtypes (SSTR2, SSTR5). Receptor activation inhibits adenylate cyclase activity, reducing cyclic AMP formation and consequently decreasing secretion of growth hormone, insulin‑like growth factor‑1, and various peptide hormones involved in tumor growth and symptom generation.

Side Effects

Lanreotid Zentiva may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

  • Injection site pain or erythema
  • Nausea or vomiting
  • Diarrhoea or abdominal cramps
  • Headache
  • Hyperglycaemia or altered glucose tolerance
  • Fatigue

Serious or Rare Side Effects

  • Gallstone formation or biliary colic
  • Acute pancreatitis
  • Severe allergic reactions (anaphylaxis, angio‑edema)
  • Cardiac arrhythmias
  • Pituitary apoplexy in patients with pre‑existing adenomas
  • Severe hepatic dysfunction

Precautions & Warnings

  • Before initiating therapy, clinicians should consider several safety aspects.
  • Monitor glucose levels: assess for hyperglycaemia, especially in diabetic patients.
  • Assess gallbladder status: evaluate for gallstones or biliary disease prior to treatment.
  • Evaluate pituitary tumor size: watch for signs of apoplexy in acromegaly patients.
  • Adjust dose in hepatic or renal impairment: use caution and consider dose modification.
  • Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Lanreotide can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Octreotide: additive suppression of hormone secretion may lead to excessive hormonal inhibition.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lanreotide plasma concentrations.
  • Cyclosporine: elevated lanreotide levels can enhance adverse effects.

Moderate Interactions (Monitor Closely)

  • Antidiabetic agents: monitor blood glucose as lanreotide may affect glycaemic control.
  • Anticoagulants: observe for altered bleeding risk.
  • Diuretics: watch electrolyte balance, especially potassium.
  • Other peptide hormone therapies: assess for overlapping pharmacodynamic effects.

Frequently Asked Questions

Lanreotid Zentiva, containing lanreotide, is indicated for the treatment of acromegaly and for symptom control in neuroendocrine tumors such as carcinoid tumors and VIPoma. It helps reduce excess hormone secretion that drives disease activity in these conditions.

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors (mainly SSTR2 and SSTR5) on target cells. This binding inhibits adenylate cyclase, lowers cyclic AMP levels, and suppresses the release of growth hormone, insulin‑like growth factor‑1, and other peptide hormones involved in tumor growth and symptom generation.

The dosage of Lanreotid Zentiva is individualized by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. Only a qualified healthcare professional can determine the appropriate dosing schedule and amount.

The safety of lanreotide in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Lanreotid Zentiva is comparable to other long‑acting somatostatin analogues such as octreotide LAR. Both provide sustained receptor activation, but lanreotide is formulated for subcutaneous administration and may have a different dosing interval, which can influence convenience and patient preference.

Lanreotid Zentiva should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability.

The medication is supplied as a sterile solution for subcutaneous injection. A healthcare professional administers the injection, typically into the abdomen or thigh, following aseptic technique and the dosing schedule prescribed by the clinician.

Serious risks include gallstone formation, acute pancreatitis, severe allergic reactions such as anaphylaxis, cardiac arrhythmias, and pituitary apoplexy in patients with pre‑existing adenomas. Patients should be monitored for these events and advised to seek immediate medical attention if symptoms arise.

Lanreotid Zentiva is contraindicated in individuals with known hypersensitivity to lanreotide or any of the formulation excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lanreotide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT